ClinicalTrials.gg
CompletedNCT00043875Updated Sep 15, 2016

Pediatric Epilepsy Trial in Subjects 1-24 Months

A Phase 2 interventional study of lamotrigine in Epilepsy, sponsored by GlaxoSmithKline. Completed at 65 sites in 14 countries. Open to participants aged 1 Month to 24 Months. Per ClinicalTrials.gov, last updated 2016-09-15.

Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
177
Allocation
Randomized
Ages
1 Month to 24 Months
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 36 studies testing lamotrigine in Epilepsy — 2 open to participants now, 2 under way, none of them phase 3. Lamotrigine · Epilepsy.

Enrollment
10th of 36
177 · median 76
Started
2000
with 2 others
Phase 2
2 of 36
none open now
Registered
1st of 36
by date
Lead sponsor
19 of 36
GlaxoSmithKline

Among the 36 studies testing lamotrigine in Epilepsy, this one is the 10th largest by enrollment, is one of 3 that started in 2000, is one of 2 in phase 2, and was the 1st registered.

Epilepsy

1,848 studies on the registry are indexed under Epilepsy; 419 are open to participants now.

Browse Epilepsy studies →

Open to participants now

2 of the 36 studies testing lamotrigine in Epilepsy are open now. Recruiting first, the newest first:

All 2 open studies →

About lamotrigine

Lamotrigine: first FDA approval 1994 (LAMICTAL). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 284 Epilepsy studies recruiting now, 114 (40%) set no upper age limit and 147 (52%) stop at 75 or younger; 139 take children under 18; 55 take healthy volunteers.

This study: 1 Month to 24 Months · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies testing lamotrigine in Epilepsy, or all of them as a file.
02

Study summary

This study is being conducted to evaluate the effectiveness and safety of LAMICTAL added to the current therapy of pediatric patients age 1-24 months old with partial seizures. The medication used in this study has been approved by FDA for the adjunctive treatment of partial seizures in patients 2 years and older.

03

Conditions studied

  • Epilepsy

Keywords

  • partial seizures
  • pediatric
  • epilepsy
04

Who can participate

Ages eligible
1 Month to 24 Months
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have a confident diagnosis of epilepsy
  • Must be experiencing 4 or more reliably detectable partial seizures per month while receiving at least 1 anti-epileptic drug (AED)
  • Must weigh at least 7 lbs if currently receiving enzyme inducing antiepileptic drugs (EIADs) OR weigh at least 15 lbs if currently receiving non-enzyme inducing antiepileptic drugs (non-EIADs)
  • Have no underlying chronic metabolism problems
  • Have normal lab results
  • Have a normal (ECG)

Exclusion criteria

EXCLUSION CRITERIA:

  • Have a diagnosis of severe, progressive myoclonus.
  • Have seizures not related to epilepsy.
  • Have previously demonstrated sensitivity or allergic reaction to the study drug or its related compounds.
  • Have progressive or unstable condition of the nervous system.
  • Used experimental medication within 30 of enrollment into the study.
  • Have any significant, chronic heart, kidney, liver or stomach/intestinal (GI) condition.
  • Current use of the medication felbamate.
  • Current use of adrenocorticotrophic hormone (ACTH).
  • Following a ketogenic diet.
  • Receiving vagal nerve stimulation (VNS).
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
177 participants (actual)

Interventions

06

What researchers measure

Primary outcomes

  1. The efficacy of LAMICTAL add-on therapy will be measured by the proportion of subjects who meet escape criteria during the Double-Blind Phase.

    Time frame: 36 Months

Secondary outcomes

  1. Time to escape patterns in Double-Blind phase. Reduction in partial seizure frequency at end of Open-Label Phase. Investigators' global evaluation of subjects' status at end of Open-Label and Double-Blind Phases; Standard pharmacokinetics; Adverse Events

    Time frame: 36 Months

07

Study locations

65 sites
  • GSK Investigational Site
    Tucson, Arizona 85712, United States
  • GSK Investigational Site
    Little Rock, Arkansas 72202, United States
  • GSK Investigational Site
    Los Angeles, California 90027, United States
  • GSK Investigational Site
    Los Angeles, California 90095, United States
  • GSK Investigational Site
    Stanford, California 94305-5235, United States
  • GSK Investigational Site
    Denver, Colorado 80218, United States
  • GSK Investigational Site
    Washington, District of Columbia 20010, United States
  • GSK Investigational Site
    Jacksonville, Florida 32207, United States
  • GSK Investigational Site
    Miami, Florida 33155-3009, United States
  • GSK Investigational Site
    Orlando, Florida 32835, United States
  • GSK Investigational Site
    Tallahassee, Florida 32308, United States
  • GSK Investigational Site
    Tampa, Florida 33607-6350, United States
  • GSK Investigational Site
    Atlanta, Georgia 30342, United States
  • GSK Investigational Site
    Augusta, Georgia 30912, United States
  • GSK Investigational Site
    Lexington, Kentucky 40536-0284, United States
  • GSK Investigational Site
    St. Paul, Minnesota 55102-2383, United States
  • GSK Investigational Site
    Kansas City, Missouri 64108, United States
  • GSK Investigational Site
    Cherry Hill, New Jersey 8034, United States
  • GSK Investigational Site
    Syracuse, New York 13210, United States
  • GSK Investigational Site
    Chapel Hill, North Carolina 27599, United States
  • GSK Investigational Site
    Raleigh, North Carolina 27607, United States
  • GSK Investigational Site
    Akron, Ohio 44308-1062, United States
  • GSK Investigational Site
    Cleveland, Ohio 44106, United States
  • GSK Investigational Site
    Columbus, Ohio 43205, United States
  • GSK Investigational Site
    Portland, Oregon 97227, United States
  • GSK Investigational Site
    Portland, Oregon 97239, United States
  • GSK Investigational Site
    Pittsburgh, Pennsylvania 15213-2583, United States
  • GSK Investigational Site
    Nashville, Tennessee 37212, United States
  • GSK Investigational Site
    Dallas, Texas 75230, United States
  • GSK Investigational Site
    Fort Worth, Texas 76104, United States
  • GSK Investigational Site
    Houston, Texas 77030, United States
  • GSK Investigational Site
    Charlottesville, Virginia 22908, United States
  • GSK Investigational Site
    Norfolk, Virginia 23510, United States
  • GSK Investigational Site
    Richmond, Virginia 23298, United States
  • GSK Investigational Site
    South Brisbane, Queensland 4101, Australia
  • GSK Investigational Site
    Parkville, Melbourne, Victoria 3050, Australia
  • GSK Investigational Site
    West Heidleberg, Melbourne, Victoria, Australia
  • GSK Investigational Site
    Perth, Western Australia, Australia
  • GSK Investigational Site
    Tallinn, 13419, Estonia
  • GSK Investigational Site
    Tartu, 51014, Estonia
  • GSK Investigational Site
    Reims Cedex, 51092, France
  • GSK Investigational Site
    Budapest, 1094, Hungary
  • GSK Investigational Site
    Debrecen, 4012, Hungary
  • GSK Investigational Site
    Miskolc, 3526, Hungary
  • GSK Investigational Site
    Szeged, 6720, Hungary
  • GSK Investigational Site
    Napoli, Campania 80131, Italy
  • GSK Investigational Site
    Bologna, Emilia-Romagna 40138, Italy
  • GSK Investigational Site
    Mantova, Lombardia 46100, Italy
  • GSK Investigational Site
    Milano, Lombardia 20133, Italy
  • GSK Investigational Site
    Messina, Sicilia 98125, Italy
  • GSK Investigational Site
    Padova, Veneto 35128, Italy
  • GSK Investigational Site
    Riga, LV 1004, Latvia
  • GSK Investigational Site
    Beirut, 11072020, Lebanon
  • GSK Investigational Site
    Kaunas, LT-50009, Lithuania
  • GSK Investigational Site
    Groningen, 9713 GZ, Netherlands
  • GSK Investigational Site
    Rotterdam, 3015 GD, Netherlands
  • GSK Investigational Site
    Utrecht, 3584 EA, Netherlands
  • GSK Investigational Site
    Coimbra, 3000-075, Portugal
  • GSK Investigational Site
    Lisboa, 1150, Portugal
  • GSK Investigational Site
    Porto, 4099-001, Portugal
  • GSK Investigational Site
    Banska Bystrica, 975 17, Slovakia
  • GSK Investigational Site
    Bratislava, 833 40, Slovakia
  • GSK Investigational Site
    Presov, 080 01, Slovakia
  • GSK Investigational Site
    Las Palmas De Gran Canaria, 35016, Spain
  • GSK Investigational Site
    Ankara, Turkey
08

References and documents

Individual participant data

Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2000, a primary completion of Nov 2003 and a completion of Nov 2003. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 14, 2002
First posted
Aug 15, 2002
Start
May 2000
Primary completionActual
Nov 2003
CompletionActual
Nov 2003
Last update
Sep 15, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 15, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00043875
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Aug 15, 2002
Start date
May 2000
Primary completion
Nov 2003
Completion
Nov 2003
Last update
Sep 15, 2016

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lamotrigine

Start the discussion